Vertex reports fourth quarter and full year 2024 financial results

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today reported consolidated financial results for the fourth quarter and full year ended december 31, 2024, and provided its full year 2025 financial guidance. “2024 marked a year of tremendous growth for vertex and we anticipate 2025 will be another important year with the landmark journavx approval and launch for moderate-to-severe acute pain; the launch of our fifth cf medicine, alyftrek; the continuing global launch.
VRTX Ratings Summary
VRTX Quant Ranking